Biodistribution of gold nanoparticles synthesized by γ-irradiation after intravenous administration in mice

Quang Luan Le¹, Thi Phuong Linh Do², Huynh Phuong Uyen Nguyen¹, Van Phu Dang³ and Quoc Hien Nguyen³

¹Center for Nuclear Techniques, 217 Nguyen Trai Street, 1 District, Ho Chi Minh City, Vietnam
²Institute of Malarialogy—Parasitology—Entomology in Ho Chi Minh City, 699 Tran Hung Dao Street, 5 District, Ho Chi Minh City, Vietnam
³Research and Development Center for Radiation Technology, 202A, 11 Street, Linh Xuan Ward, Thu Duc District, Ho Chi Minh City, Vietnam

E-mail: hien7240238@yahoo.com

Received 7 February 2014
Accepted for publication 12 March 2014
Published 7 May 2014

Abstract

In the present research work we evaluate the in vivo distribution of gold nanoparticles (AuNPs) at different time durations after intravenous administration in mice. AuNPs with size of about 20 nm and concentration of 1 mM were synthesized by gamma irradiation method using 0.5% alginate as a stabilizer. AuNPs were characterized by UV-Vis spectrum and transmission electron microscope (TEM) image. The as-synthesized AuNPs solution was centrifuged to concentrate to 2 mg AuNPs/1 ml solution. Intravenous administration of AuNPs in mice was done at the tail with 1 mg AuNPs (0.5 ml). After 1, 3, 6 and 12 h of injection, blood was collected, mice were sacrificed and various tissues/organs were removed. The blood haematology and serum clinical chemistry indexes of mice intravenously injected with AuNPs were not significantly different compared to those of the control ones. In addition, gold content in the samples was quantitatively determined by k0-neutron activation analysis (k0-NAA) at nuclear research reactor, Da Lat Vietnam. Results showed that after 1 h of administration, AuNPs were mainly accumulated in blood (41.56%), in liver (51.60%), in lung (6.16%) and in kidney (0.53%). After that the content of AuNPs in blood was decreased to nearly normal at 6 h while the content of AuNPs in liver, lung and kidney was accumulatively increased. After 6 h of administration AuNPs were mainly accumulated in organs like liver (76.33%), lung (11.86%) and kidney (2.23%). Thus, the obtained results are practically useful for using AuNPs as x-ray contrast agent, especially for blood and liver.

Keywords: gold nanoparticles, γ-irradiation, in vivo distribution, mice

1. Introduction

Colloidal gold nanoparticles (AuNPs) are emerging as a lead candidate of the nanocarriers in the field of nanopharmaceuticals, as AuNPs have good biocompatibility and can be conjugated to protein and other molecular species without altering their biological activity [1]. AuNPs are used for many applications especially in bioscience and medical fields [2, 3] such as cancer diagnose and therapy [4–8], carriers for transmucosal delivery of insulin [9], x-ray contrast agent [10] etc. AuNPs can also be used in the cosmetics field particularly for facial mask or cream because AuNPs help to improve blood circulation, skin elasticity, and can rejuvenate the skin and reduce the formation of wrinkles [11]. Different methods can
be used for synthesis of AuNPs and compared to other methods, gamma Co-60 ray irradiation is considered as an effective method due to several advantages such as: (1) the reaction is carried out at room temperature; (2) yield of AuNPs is high; (3) AuNPs can be purely prepared without contamination of excessive chemical reductant and Au³⁺ ions residue; (4) the size of AuNPs is easily controlled by varying Au³⁺ ions or seed enlargement approach [12, 13]; (5) mass production can be carried out and (6) processing is satisfied to requirement of clean production [14]. According to Lasagna-Reeves et al [15], for applications of AuNPs in therapy and drug delivery it is necessary to study the bioaccumulation and toxic effect of different doses as well as to choose the appropriate size of AuNPs.

In the present study, AuNPs of 20 nm and concentration of 1 mM were synthesized by gamma Co-60 irradiation method using alginate as stabilizer, as reported in our previous paper [12]. Intra-veneous administration of AuNPs in mice was done and blood haematology and serum clinical chemistry indexes were investigated. In addition, AuNPs accumulation in blood, liver, lung and kidney after intravenous administration was also determined.

2. Experimental

2.1. Materials

Hydrogen tetrachloroauratetrihydrate (HAuCl₄·3H₂O), pure water from Merck, Germany and sodium alginate (M₅₋₅ = 4.35 × 10⁵ g mol⁻¹) from Hayashi Pure Chemical Industry Ltd, Japan were used as received. Glassware was treated with regia solution (1 V HNO₃ : 3 V HCl), washed with pure water and dried.

2.2. Preparation of Au³⁺/alginate solution and irradiation

Two stock solutions, particularly 10 mM Au³⁺ and 2% alginate were prepared by dissolving HAuCl₄·3H₂O and alginate into water. Au³⁺ 1 mM/alginate 0.5% solution was prepared by pouring Au³⁺ solution into alginate solution with desired concentration while stirring for about 10 min. Then the prepared Au³⁺/alginate solution of 200 ml was put into a glass bottle with plastic cap. Irradiation was carried out on the gamma Co-60 irradiator STSVCo-60/B at a dose of 8 kGy with dose rate of 1.3 kGy h⁻¹ at VINAGAMMA Center in Ho Chi Minh City.

2.3. Characterization of AuNPs/alginate

The absorption spectrum of AuNPs solution, which was diluted by water to 0.1 mM calculated as Au³⁺ concentration, was taken on a UV-Vis spectrophotometer model UV-2401PC, Shimadzu. The size and size distribution of the AuNPs were characterized by TEM images on transmission electron microscope (TEM) model JEM1010 (JEOL, Japan) and statistically calculated from about 300 particles.

2.4. Intravenous administration in mice

Mice of the Swiss line were supplied by Pasteur Institute of Ho Chi Minh City and fed at Institute of Malarialogy-Parasitology-Entomology in Ho Chi Minh City for 8 weeks and their average body weight was about 30 g. The mice were then injected with 0.5 ml AuNPs solution containing 1 mg gold via a tail vein. The control mice were also intravenously injected by 0.5 ml of 0.5% alginate solution without AuNPs.

2.5. Haematology analysis

The blood of mice after intravenous AuNPs injection at 0, 1, 3, 6 and 12 h was collected and put into tubes containing heparin for analysis. Haematology indexes including haematocrit (Htc), haemoglobin (Hb), total white (WBC) and red (RBC) blood cell counts, lymphocytes (Lympho), monocytes (Mono), and granulocytes (GR) counts, mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), and mean corpuscular haemoglobin concentration (MCHC) were analyzed by the 18 parameters celltac α (Nihon Kohden, Japan) automatic haematology analyzer.

2.6. Serum clinical chemistry analysis

The blood of injected mice was collected in the same way as haematology analysis. The blood was then centrifuged at 5000 rpm for 10 min to separate the serum for analysis. Serum clinical chemistry indexes including glucose (Glu), creatine...
(CR), aspartate aminotransferase (AST), alanine aminotransferase (ALT), globin (GLB) and albumin (ALB) were analyzed by BioSystem A17 analyzer (Belgium).

2.7. Gold analysis

The mice after intravenous AuNPs injection were killed and the liver, kidney, lung and blood at 0, 1, 3, 6 and 12 h were collected. The tissues were then dried at 180 °C for 5 h and the content of gold in each tissue was quantitatively analyzed at Da Lat Nuclear Research Institute by k0-neutron activation analysis (k0-NAA) method as described by Abd et al [17].

3. Results and discussion

3.1. Synthesis and characterization of AuNPs

The UV-Vis spectrum of AuNPs solution in figure 1(a) showed the maximum absorption wavelength (λmax) at 530 nm for Au3+ concentration of 1 mM. The TEM image and particles size distribution are shown in figures 1(b) and (c). The average diameter of AuNPs was determined to be about 20 nm with a fairly narrow Gaussian distribution.

Different AuNPs sizes can be pre-selected by varying Au3+ concentration and/or seed enlargement approach. [12–14, 16] According to Anh et al [12] gamma Co-60 irradiation method is suitable for production of AuNPs with controllable size and high purity.

3.2. Toxicity test

Since the intravenous administration was proposed as the best way for application of AuNPs in medical fields such as cancer diagnostics and therapy [4–8], carriers for transmucosal delivery of insulin [9], x-ray contrast agent [10] etc. The toxicity test of AuNPs after intravenous administration is very important. In this study, 10 blood haematology indexes (Htc, Hgb, RBC, WBC, GR, Lympho, Mono, MCV, MCH and MCHC) of intravenous AuNPs injected mice and control mice were analyzed at 1, 3, 6 and 12 h after injection. The results in table 1 show that there was no significant difference in blood haematology indexes between control and AuNPs injected mice.

Table 1. Blood haematology of mice intravenously injected with 1 mg AuNPs.

| Treatment      | Hct (%) | Hgb (g/dL) | RBC (10⁶/μl) | MCV (fL) | MCH (Pg) | MCHC (g/dL) | WBC (10³/μl) | Mono (%) | Lympho (%) | GR (%) |
|----------------|---------|------------|--------------|----------|----------|-------------|--------------|----------|------------|--------|
| 1 h control    | 40.03   | 13.9       | 4.59         | 87.56    | 30.30    | 34.73       | 6.39         | 0.25     | 2.29       | 3.86   |
| 1 h injected   | 40.66   | 14.7       | 4.76         | 87.16    | 33.23    | 34.00       | 6.43         | 0.30     | 2.30       | 3.83   |
| Statistically  | NS      | NS         | NS           | NS       | NS       | NS          | NS           | NS       | NS         | NS     |
| 3 h control    | 43.40   | 14.1       | 5.38         | 86.00    | 26.96    | 33.50       | 6.59         | 0.26     | 2.43       | 3.90   |
| 3 h injected   | 46.90   | 16.5       | 5.50         | 85.33    | 30.20    | 35.10       | 7.11         | 0.31     | 2.93       | 3.86   |
| Statistically  | NS      | NS         | NS           | NS       | NS       | NS          | NS           | NS       | NS         | NS     |
| 6 h control    | 39.53   | 14.1       | 4.13         | 95.00    | 33.33    | 35.40       | 6.30         | 0.44     | 2.16       | 3.69   |
| 6 h injected   | 40.86   | 14.9       | 4.40         | 92.96    | 33.86    | 36.56       | 6.23         | 0.43     | 2.13       | 3.66   |
| Statistically  | NS      | NS         | NS           | NS       | NS       | NS          | NS           | NS       | NS         | NS     |
| 12 h control   | 40.93   | 13.6       | 5.32         | 77.00    | 25.66    | 33.23       | 6.40         | 0.45     | 2.23       | 3.93   |
| 12 h injected  | 37.53   | 13.4       | 5.43         | 69.30    | 26.70    | 35.70       | 6.62         | 0.46     | 2.30       | 3.90   |
| Statistically  | NS      | NS         | NS           | NS       | NS       | NS          | NS           | NS       | NS         | NS     |

NS: No significant difference by T-test with probability level >0.95.

Table 2. Serum clinical chemistry of mice intravenously injected with 1 mg AuNPs.

| Treatment      | GLU (mg/dl) | AST (unit/l) | ALT (unit/l) | Ure (mg/dl) | CR (mg/dl) | ALB (g/dl) | TP (g/dl) | TBLI (mg/dl) |
|----------------|-------------|--------------|--------------|-------------|------------|------------|------------|--------------|
| 1 h control    | 160.00      | 41.33        | 47.13        | 27.93       | 0.18       | 3.53       | 6.23       | 0.17         |
| 1 h injected   | 208.67      | 42.00        | 54.67        | 32.67       | 0.32       | 3.47       | 4.97       | 0.21         |
| Statistically  | NS          | NS           | NS           | NS          | NS         | NS         | NS         | NS           |
| 3 h control    | 222.00      | 38.66        | 45.67        | 24.93       | 0.20       | 2.63       | 5.73       | 0.29         |
| 3 h injected   | 243.33      | 42.00        | 55.67        | 20.06       | 0.19       | 2.83       | 5.93       | 0.25         |
| Statistically  | NS          | NS           | NS           | NS          | NS         | NS         | NS         | NS           |
| 6 h control    | 182.00      | 31.33        | 46.30        | 28.13       | 0.17       | 2.50       | 5.73       | 0.31         |
| 6 h injected   | 210.00      | 32.67        | 37.73        | 29.73       | 0.19       | 2.53       | 5.23       | 0.28         |
| Statistically  | NS          | NS           | NS           | NS          | NS         | NS         | NS         | NS           |
| 12 h control   | 119.67      | 29.00        | 46.67        | 28.33       | 0.17       | 2.59       | 4.96       | 0.29         |
| 12 h injected  | 125.33      | 30.33        | 47.00        | 32.30       | 0.15       | 2.91       | 5.80       | 0.30         |
| Statistically  | NS          | NS           | NS           | NS          | NS         | NS         | NS         | NS           |

NS: No significant difference by T-test with probability level >0.95.
Table 2 records the serum clinical chemistry indexes of AuNPs injected and control mice. The results also showed that the contents of glucose, creatine, aspartate aminotransferase, alanine aminotransferase, total protein, total bilirubin and albumin of AuNPs injected mice were not significantly different from those of control mice. The analyzed results on haematology and serum clinical chemistry of tested mice proved that AuNPs were not toxic by the intravenous administration at a dose of 1 mg/mouse (30 g). The results are in good agreement with those reported by Hainfeld et al [10].

3.3. In vivo distribution of AuNPs

The distribution of AuNPs in different tissues of mice is displayed in figure 2. The results indicated that the concentration of AuNPs in blood decreased with time, the gold content almost disappeared after 6 h injection (0.01 mg per 1 gram fresh tissue) and the blood became normal at 12 h after injection. The results in figure 2 also indicated that at 1 h after injection, AuNPs penetrated into liver, kidney and lung. At 6 h after post injection, AuNPs were mainly distributed in liver and lung tissue, in particular, the gold content in liver tissue was found to be about 0.56 mg per 1 gram fresh tissue and attained 76.33% of injected dose, while at the same time the gold content in lung tissue was found to be about 0.45 mg per 1 gram fresh tissue and attained 11.86% of injected dose. The gold content in kidney was lower than that in liver and lung (0.06 mg per 1 gram fresh tissue and only 2.23% of injected dose). At 12 h after injection, the gold content decreased in all tissues. The results in figure 2 also indicated that after injection, AuNPs transferred from blood into other tissues and mostly accumulated in liver and lung with the maximal concentration at 6 h after injection.

Thus, the AuNPs/alginate product with particle diameter of about 20 nm synthesized by gamma Co-60 irradiation using alginate (0.5%) as stabilizer is not toxic to mice by intravenous injection at a dose of 33.3 mg AuNPs kg\(^{-1}\) body weight. The AuNPs did not produce any mortality or gross behavioral changes in mice at the doses studied; all animals experimented on were healthy and had normal weight development. Porkharkar et al reported that LD\(_{50}\) (dose required to kill half of the population) value of AuNPs/chitosan was found to be greater than 2000 mg kg\(^{-1}\) body weight of rats by oral administration [19]. They concluded that AuNPs/chitosan produced no toxicity in rats that can be exploited for potential therapeutic applications. Furthermore, spherical AuNPs of different sizes (5–70 nm) were reported not to be toxic to human skin cells [20]. Thus, AuNPs/alginate product is promising to apply in biomedicine, cosmetics and in other fields as well.

4. Conclusion

AuNPs with size of about 20 nm were successfully synthesized by gamma Co-60 irradiation method using alginate as a stabilizer. The AuNPs product was not toxic for mice by intravenous injection at a dose of 33.3 mg AuNPs kg\(^{-1}\). The accumulation of AuNPs was mainly concentrated in lung and liver tissue after intravenous injection. The maximal gold content was about 0.56 mg (76.33% of injected dose) and 0.45 mg (11.86% of injected dose) in 1 g fresh lung and liver tissue, respectively. Thus, gamma Co-60 irradiation is suitable tool for production of AuNPs with high purity and AuNPs/alginate can be favorably used in biomedicine and in other fields as well.

Acknowledgement

This research work was supported by the Ministry of Science and Technology of Vietnam (Project No. DTDL.2011-G/80).

References

[1] Sonavane G, Tomoda K and Makino K 2008 *Coll. Surf. B: Biointerfaces* **66** 274
[2] Baptista P et al 2008 *Anal. Bioanal. Chem.** **391** 943
[3] Boisselier E and Astruc D 2009 Chem. Soc. Rev. 38 1759
[4] Lee H et al 2008 Biomaterials 29 4709
[5] Huang X and El-Sayed M A 2010 J. Adv. Res. 1 13
[6] Mukherjee S et al 2012 Nanotechnology 23 455103
[7] Joshi P et al 2012 Coll. Surf. B: Biointerfaces 95 195
[8] Geetha R et al 2013 Cancer Nano 4 91
[9] Bhumkar D R et al 2007 Pharma. Rev. 24 1415
[10] Hainfeld J F et al 2006 Brit. J. Radiol. 79 248
[11] Fathi-Azarbayjani A et al 2010 AAPS PharSciTech. 11 1164
[12] Anh N T et al 2010 Rad. Phys. Chem. 79 405
[13] Duy N N et al 2013 Coll. Surf. A: Physico. Chem. Eng. Asp. 436 633
[14] Hien N Q et al 2012 Carbohydr. Polym. 89 537
[15] Lasagna-Reeves C et al 2010 Biochem. Biophys. Res. Commun. 392 649
[16] Li T, Park H G and Choi S H 2007 Mater. Chem. Phys. 105 325
[17] Abd A E et al 2009 J. Nucl. Radiat. Phys. 4 21
[18] Nghiem T H L et al 2012 Adv. Nat. Sci.: Nanosci. Nanotechnol. 3 015002
[19] Pokharkar V et al 2009 J. Biomed. Nanotechnol. 5 233
[20] Wang S et al 2008 Chem. Phys. Lett. 463 145